SuperworthOcugen price to sales ratio OCGN
Market value divided by revenue over the last twelve months, since 2024.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 110×
- May 2026
- Peer median
- 3.6×
Ocugen's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.
It was last meaningful in May 2026, at 110×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 110× | 77.4× | 151× |
| 2025 | 82.0× | 38.7× | 109× |
| 2024 | 52.4× | 36.6× | 74.4× |
Against its peers
Companies in Biotechnology nearest Ocugen's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| OCGNOcugen | n/m |
| PLXProtalix BioTherapeutics | 2.5× |
| MGTXMeiraGTx | 2.2× |
| VCELVericel | 7.1× |
| ADMAAdma Biologics | 4.7× |
| Peer median | 3.6× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Ocugen
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.